News & Updates

Treatment with zuranolone 50 mg/day in adults with major depressive disorder (MDD) results in greater improvements in depressive symptoms at day 15, demonstrating a rapid time to effect (day 3), and is generally well tolerated, with no new safety concerns compared with lower dosages, reports a study.

Local intranasal treatment with budesonide does not appear to be effective for persistent hyposmia in patients with nonsevere COVID-19, according to a study.

Use of zuranolone significantly improves depressive symptoms, with no serious side effects, in women with severe postpartum depression (PPD), a common perinatal complication with adverse maternal and infant outcomes, results of a phase III trial have shown.

Treatment with nonsteroidal anti-inflammatory drugs (NSAIDs) appears to increase the risk of venous thromboembolism (VTE) in women using hormonal contraception, reveals a study.

In cancer patients with isolated distal deep vein thrombosis (IDDVT), a 12-month anticoagulation regimen with the oral factor Xa inhibitor edoxaban fared better than a 3-month regimen, findings from the ONCO DVT study have shown.

Treatment with low-dose spironolactone results in reduced albuminuria without causing hyperkalaemia in patients with type 2 diabetes (T2D), reports a study.

Faecal microbiota transplantation helps reduce abdominal bloating but not the overall symptoms in patients with irritable bowel syndrome (IBS), according to a small study.